What is treated in hemostasis?

Hemostasis covers qualitative or quantitative deficits in clotting factors that can cause chronic and severe diseases. These often require life-long care.

Coagulation factors, LFB expertise

There are a variety of coagulation diseases and disorders. For years, LFB has developed expertise in the field of hemostasis which allows it to offer health professionals treatment options for hemophilia A and B (factors VIII and IX), Willebrand disease (Willebrand factor) and coagulation factor XI deficiency (factor XI).

Treatment solutions for extremely rare disorders

Hemophilia affects several thousands of people in France, and consists in a deficiency of factor VIII (hemophilia A) or IX (hemophilia B, more rare). But some clotting disorders such as Willebrand disease or factor XI deficiency, affect only a few tens or hundreds of patients each year. The factor XI made by LFB BIOMEDICAMENTS is used to treat fewer than 60 patients per year in France. LFB BIOMEDICAMENTS is the only laboratory in the world to produce a plasma-derived pure Willebrand factor and one of only two laboratories providing a plasma-derived factor XI.

In a different, but equally important area, LFB BIOMEDICAMENTS is the only laboratory in France to offer a therapeutic solution for alpha-1 antitrypsin deficiency, a rare disease. LFB BIOMEDICAMENTS supports the CONEDAT cohort, (national cohort of alpha-1 antitrypsin deficient emphysema patients), which is the national register for surveying and monitoring progress in deficient patients, as well as two other cohorts of adults and children, in order to make progress in understanding this deficit from the point of view of the liver.

International development

In 2010, LFB took an important step in terms of its international development with its Willebrand factor, the only medicinal product in the world to be derived from pure plasma.

LFB launched a joint reconnaissance procedure, which was received favourably in 15 new European countries. On the basis of this positive opinion, the various countries that were involved will be able to award MAs to the Willebrand factor. In 2011, this factor will be available in 22 countries in the European Union, representing 93 % of the total European population.